000			01912 a2200529 4500
005			20250517174925.0
264		0	_c20180706
008			201807s 0 0 eng d
022			_a1473-5687
024	7		_a10.1097/MEG.0000000000000963 _2doi
040			_aNLM _beng _cNLM
100	1		_aMohamed, Mohamed S
245	0	0	_aSofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients. _h[electronic resource]
260			_bEuropean journal of gastroenterology & hepatology _cDec 2017
300			_a1368-1372 p. _bdigital
500			_aPublication Type: Journal Article; Observational Study
650	0	4	_aAdult
650	0	4	_aAlanine Transaminase _xblood
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aAspartate Aminotransferases _xblood
650	0	4	_aBilirubin _xblood
650	0	4	_aCarbamates
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEgypt
650	0	4	_aEnd Stage Liver Disease _xphysiopathology
650	0	4	_aFemale
650	0	4	_aHepatitis C, Chronic _xblood
650	0	4	_aHumans
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aInternational Normalized Ratio
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPlatelet Count
650	0	4	_aProspective Studies
650	0	4	_aPyrrolidines
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aSerum Albumin _xmetabolism
650	0	4	_aSeverity of Illness Index
650	0	4	_aSofosbuvir _xtherapeutic use
650	0	4	_aSustained Virologic Response
650	0	4	_aValine _xanalogs & derivatives
700	1		_aHanafy, Amr S
700	1		_aBassiony, Mohamed A A
700	1		_aHussein, Samia
773	0		_tEuropean journal of gastroenterology & hepatology _gvol. 29 _gno. 12 _gp. 1368-1372
856	4	0	_uhttps://doi.org/10.1097/MEG.0000000000000963 _zAvailable from publisher's website
999			_c27607057 _d27607057